Abstract
This study evaluated the efficacy of emamectin benzoate, 0.2% aquaculture premix, against sea lice on Atlantic salmon in eastern Canada. Salmon pens received either emamectin benzoate, orally, in feed at 50 micrograms/kg body weight/day for 7 consecutive days, or the same diet with no added medication. The site veterinarian had the option of administering a bath treatment with azamethiphos to any pen in the trial. The mean number of lice per fish was lower (P < 0.05) in the experimental group when measured 1, 3, 4, and 6 weeks after the start of medication. Treatment efficacy was 70%, 88%, 95%, and 61%, respectively. Three azamethiphos bath treatments were applied to each control pen during the trial, while the treatment pens received no bath treatment. No gravid female parasites were observed on any fish in the treatment group, while these life stages were observed on fish in the control group. Orally administered emamectin benzoate was palatable and highly effective for control of sea lice on salmon.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- O'Halloran J., Hogans W. E. First use in North America of azamethiphos to treat Atlantic salmon for sea lice infestation: procedures and efficacy. Can Vet J. 1996 Oct;37(10):610–611. [PMC free article] [PubMed] [Google Scholar]
- Pike A. W. Sea lice--major pathogens of farmed atlantic salmon. Parasitol Today. 1989 Sep;5(9):291–297. doi: 10.1016/0169-4758(89)90020-3. [DOI] [PubMed] [Google Scholar]